서방형 부형제 시장 규모, 점유율 및 동향 분석 보고서 : 투여 경로별, 기술별, 제품별, 지역별, 부문별 예측(2023-2030년)

Sustained Release Excipients Market Growth & Trends

The global sustained release excipients market size is expected to reach USD 2.36 billion by 2030, expanding at a CAGR of 8.4% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of the sustained-release excipients market is attributable to the growing demand for sustained-release drugs, the improvement in patient compliance rate, and the multiple advantages of this drug-delivery method over conventional methods. These excipients are usually used as capsules and tablet formulations to release the drug slower; thereby, the drug has to be taken at less frequent intervals making it advantageous over immediate-release formulations. The sustained release of excipients' disintegration, dissolution, or degradation leads to the modified slower drug release.

Reduced dosage frequency, improved patient compliance, maintenance of the constant level of drug in blood plasma, lower instances of toxicity due to overdose, and higher cost-effectiveness, in the long run, are some of the major advantages of using sustained release drug delivery systems. Regular consumption of oral conventional drugs generally results in undesired symptoms, such as gastrointestinal upset, cramps, nausea, and diarrhea. The use of sustained release drug formulations provides patients relief from these symptoms and helps maintain desired therapeutic drug levels in the body. Moreover, these have been increasing the adoption of sustained-release formulations, enabling higher patient compliance and improved therapeutic effect.

Over the past few years, there has been a global rise in antibiotic resistance. Overuse and misuse of conventional drug formulations have been identified as the major cause of antibiotic resistance. In some instances, patients recover within a few days of drug administration and discontinue the recommended dose of drugs, culminating in resistance. Such resistance leads to higher medical costs, longer hospital stays, and a rise in mortality rate. The rise in the incidence of infectious and chronic diseases has also resulted in antibiotic resistance, which has negatively impacted the conventional dosage forms market. Thus, alternative procedures to treat and manage these diseases are being implemented.

Controlled release formulations have been extensively accepted among physicians to prevent antibiotic resistance. Since these formulations generate preferred therapeutic drug levels in blood plasma and decrease the dosage frequency, they are an ideal choice among physicians, increasing their demand in the industry. The impact of disruptions on pharmaceutical production and subsequently on excipient demand affected by lockdowns and transport and travel bans across several countries due to the COVID-19 pandemic will be comparatively short-term. However, the supply disruptions due to extended lockdowns in different countries may substantially impact the oral solid dosage form drug manufacturing.

This, in turn, will significantly impact the excipients' demand growth globally. There is a wide scope for industry growth in Europe, including France, Spain, and Italy. This is due to the rising adoption of advanced drugs in these countries. Moreover, regulatory authorities, such as the European Medicines Agency (EMA) and Medicines & Healthcare Products Regulatory Agency (MHRA), are constantly working toward ensuring high safety standards and easy access to low-cost drugs in this region. High disposable income, sophisticated healthcare infrastructure, and a rise in product approvals are expected to create growth opportunities in Europe.

Key players in the market are introducing new products to continuously meet the changing requirements of consumers in the pharmaceutical industry. For instance, in November 2022, Roquette Freres announced the launch of Pearlitol CR-H, enhancing API's sustained release in compression formulations. It further enhances the tableting process giving it a competitive edge.

Sustained Release Excipients Market Report Highlights

• Polymers product segment accounted for the largest share in 2022. Varied usage of polymers in sustained-release formulations is anticipated to fuel industry growth
• Conventional use of the oral delivery route has contributed to the fastest growth of the segment. Convenience, in terms of storage, premeasured doses, portability, and the noninvasive nature of this route are some of the major factors accelerating its adoption
• The rising adoption of transdermal patches has contributed to the fastest growth of the segment
• Targeted drug delivery constituted the largest revenue share in 2022, as a large number of industry players have strong product portfolios. Implantable sustained-release drug delivery systems have improved efficiency, lower adverse effects, and higher convenience, which impels segment growth
• North America dominated the global industry in 2022 owing to the high investments in R&D and the availability of highly sophisticated technologies in the region
• Asia Pacific is projected to register the fastest CAGR during the forecast period due to the growing pharmaceutical industry in emerging countries, such as India and China
• A few of the key market players include Roquette Freres, BASF, International Flavors & Fragrances, Inc., Ashland, Evonik Industries AG, Croda International Plc, and Gattefosse

Table of Contents

Chapter 1. Methodology and Scope

• 1.1 Market Segmentation and Scope
  • 1.1.1 Segment Definitions
    • 1.1.1.1 Product Segment
    • 1.1.1.2 Technology Segment
    • 1.1.1.3 Route Of Administration Segment
• 1.2 Regional Scope
• 1.3 Estimates And Forecast Timeline
• 1.4 Objectives
  • 1.4.1 Objective - 1
  • 1.4.2 Objective - 2
  • 1.4.3 Objective - 3
• 1.5 Research Methodology
• 1.6 Information Procurement
  • 1.6.1 Purchased Database
  • 1.6.2 Gvr's Internal Database
  • 1.6.3 Secondary Sources
  • 1.6.4 Primary Research
• 1.7 Information Or Data Analysis
  • 1.7.1 Data Analysis Models
• 1.8 Market Formulation & Validation
• 1.9 Model Details
  • 1.9.1 Commodity Flow Analysis
• 1.10 List Of Secondary Sources
• 1.11 List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Trends and Outlook
• 3.4. Market Dynamics
  • 3.4.1. Increased benefits over conventional dosage forms
  • 3.4.2. Necessity of pediatric and geriatric sustained release dosage forms
  • 3.4.3. Antibiotic resistance
• 3.5. Market Restraint Analysis
  • 3.5.1. Drug toxicity due to dose dumping
  • 3.5.2. Need for high dose of API
• 3.6. Business Environment Analysis
  • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.6.2. Porter's Five Forces Analysis
• 3.7. COVID-19 Impact Analysis
• 3.8. Market Opportubnity and Challenge Analysis

Chapter 4. Product Business Analysis

• 4.1. Sustained Release Excipients Market: Product Movement Analysis
• 4.2. Gelatin
  • 4.2.1. Gelatin Market, 2018 - 2030 (USD Million)
• 4.3. Polymers
  • 4.3.1. Polymers Market, 2018 - 2030 (USD Million)
• 4.4. Minerals
  • 4.4.1. Minerals Market, 2018 - 2030 (USD Million)
• 4.5. Sugars
  • 4.5.1. Sugars Market, 2018 - 2030 (USD Million)
• 4.6. Alcohols
  • 4.6.1. Alcohols Market, 2018 - 2030 (USD Million)
• 4.7. Chitosan
  • 4.7.1. Chitosan Market, 2018 - 2030 (USD Million)

Chapter 5. Technology Business Analysis

• 5.1. Sustained Release Excipients Market: Technology Movement Analysis
  • 5.1.1. Targeted Delivery
• 5.2. Targeted Delivery Market, 2018 - 2030 (USD Million)
  • 5.2.1. Micro Encapsulation
• 5.3. Micro Encapsulation Market, 2018 - 2030 (USD Million)
  • 5.3.1. Wurster Technique
• 5.4. Wurster Technique Market, 2018 - 2030 (USD Million)
  • 5.4.1. Transdermal
• 5.5. Transdermal Market, 2018 - 2030 (USD Million)
  • 5.5.1. Implants
• 5.6. Implants Market, 2018 - 2030 (USD Million)
  • 5.6.1. Coacervation
• 5.7. Coacervation Market, 2018 - 2030 (USD Million)
• 5.8. Others
  • 5.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Application Business Analysis

• 6.1. Sustained Release Excipients Market: Route of Administration Movement Analysis
• 6.2. Oral
  • 6.2.1. Oral Market, 2018 - 2030 (USD Million)
• 6.3. Intramuscular
  • 6.3.1. Intramuscular Market, 2018 - 2030 (USD Million)
• 6.4. Subcutaneous
  • 6.4.1. Subcutaneous Market, 2018 - 2030 (USD Million)
• 6.5. Transdermal
  • 6.5.1. Transdermal Market, 2018 - 2030 (USD Million)
• 6.6. Vaginal
  • 6.6.1. Vaginal Market, 2018 - 2030 (USD Million)
• 6.7. Ophthalmic
  • 6.7.1. Ophthalmic Market, 2018 - 2030 (USD Million)
• 6.8. Intravenous
  • 6.8.1. Intravenous Market, 2018 - 2030 (USD Million)
• 6.9. Others
  • 6.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

• 7.1. Sustained Release Excipients Market Share By Region, 2022 & 2030
• 7.2. North America
  • 7.2.1. SWOT Analysis
  • 7.2.2. North America Sustained Release Excipients Market, 2018 - 2030 (USD Million)
  • 7.2.3. U.S.
    • 7.2.3.1. Key Country Dynamics
    • 7.2.3.2. Target Disease Prevalence
    • 7.2.3.3. Competitive Scenario
    • 7.2.3.4. Regulatory Framework
    • 7.2.3.5. Reimbursement Scenario
    • 7.2.3.6. U.S. Sustained Release Excipients Market, 2018 - 2030 (USD Million)
  • 7.2.4. Canada
    • 7.2.4.1. Key Country Dynamics
    • 7.2.4.2. Target Disease Prevalence
    • 7.2.4.3. Competitive Scenario
    • 7.2.4.4. Regulatory Framework
    • 7.2.4.5. Reimbursement Scenario
    • 7.2.4.6. Canada Sustained Release Excipients Market, 2018 - 2030 (USD Million)
• 7.3. Europe
  • 7.3.1. SWOT Analysis
  • 7.3.2. Europe Sustained Release Excipients Market, 2018 - 2030 (USD Million)
  • 7.3.3. Germany
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Target Disease Prevalence
    • 7.3.3.3. Competitive Scenario
    • 7.3.3.4. Regulatory Framework
    • 7.3.3.5. Reimbursement Scenario
    • 7.3.3.6. Germany Sustained Release Excipients Market, 2018 - 2030 (USD Million)
  • 7.3.4. UK
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Target Disease Prevalence
    • 7.3.4.3. Competitive Scenario
    • 7.3.4.4. Regulatory Framework
    • 7.3.4.5. Reimbursement Scenario
    • 7.3.4.6. UK Sustained Release Excipients Market, 2018 - 2030 (USD Million)
  • 7.3.5. France
    • 7.3.5.1. Key Country Dynamics
    • 7.3.5.2. Target Disease Prevalence
    • 7.3.5.3. Competitive Scenario
    • 7.3.5.4. Regulatory Framework
    • 7.3.5.5. Reimbursement Scenario
    • 7.3.5.6. France Sustained Release Excipients Market, 2018 - 2030 (USD Million)
  • 7.3.6. Italy
    • 7.3.6.1. Key Country Dynamics
    • 7.3.6.2. Target Disease Prevalence
    • 7.3.6.3. Competitive Scenario
    • 7.3.6.4. Regulatory Framework
    • 7.3.6.5. Reimbursement Scenario
    • 7.3.6.6. Italy Sustained Release Excipients Market, 2018 - 2030 (USD Million)
  • 7.3.7. Spain
    • 7.3.7.1. Key Country Dynamics
    • 7.3.7.2. Target Disease Prevalence
    • 7.3.7.3. Competitive Scenario
    • 7.3.7.4. Regulatory Framework
    • 7.3.7.5. Reimbursement Scenario
    • 7.3.7.6. Spain Sustained Release Excipients Market, 2018 - 2030 (USD Million)
  • 7.3.8. Denmark
    • 7.3.8.1. Key Country Dynamics
    • 7.3.8.2. Target Disease Prevalence
    • 7.3.8.3. Competitive Scenario
    • 7.3.8.4. Regulatory Framework
    • 7.3.8.5. Reimbursement Scenario
    • 7.3.8.6. Denmark Sustained Release Excipients Market, 2018 - 2030 (USD Million)
  • 7.3.9. Sweden
    • 7.3.9.1. Key Country Dynamics
    • 7.3.9.2. Target Disease Prevalence
    • 7.3.9.3. Competitive Scenario
    • 7.3.9.4. Regulatory Framework
    • 7.3.9.5. Reimbursement Scenario
    • 7.3.9.6. Sweden Sustained Release Excipients Market, 2018 - 2030 (USD Million)
  • 7.3.10. Norway
    • 7.3.10.1. Key Country Dynamics
    • 7.3.10.2. Target Disease Prevalence
    • 7.3.10.3. Competitive Scenario
    • 7.3.10.4. Regulatory Framework
    • 7.3.10.5. Reimbursement Scenario
    • 7.3.10.6. Norway Sustained Release Excipients Market, 2018 - 2030 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. SWOT Analysis
  • 7.4.2. Asia Pacific Sustained Release Excipients Market, 2018 - 2030 (USD Million)
  • 7.4.3. Japan
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Competitive Scenario
    • 7.4.3.4. Regulatory Framework
    • 7.4.3.5. Reimbursement Scenario
    • 7.4.3.6. Japan Sustained Release Excipients Market, 2018 - 2030 (USD Million)
  • 7.4.4. China
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Competitive Scenario
    • 7.4.4.4. Regulatory Framework
    • 7.4.4.5. Reimbursement Scenario
    • 7.4.4.6. China Sustained Release Excipients Market, 2018 - 2030 (USD Million)
  • 7.4.5. India
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Target Disease Prevalence
    • 7.4.5.3. Competitive Scenario
    • 7.4.5.4. Regulatory Framework
    • 7.4.5.5. Reimbursement Scenario
    • 7.4.5.6. India Sustained Release Excipients Market, 2018 - 2030 (USD Million)
  • 7.4.6. South Korea
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Target Disease Prevalence
    • 7.4.6.3. Competitive Scenario
    • 7.4.6.4. Regulatory Framework
    • 7.4.6.5. Reimbursement Scenario
    • 7.4.6.6. South Korea Sustained Release Excipients Market, 2018 - 2030 (USD Million)
  • 7.4.7. Australia
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Target Disease Prevalence
    • 7.4.7.3. Competitive Scenario
    • 7.4.7.4. Regulatory Framework
    • 7.4.7.5. Reimbursement Scenario
    • 7.4.7.6. Australia Sustained Release Excipients Market, 2018 - 2030 (USD Million)
  • 7.4.8. Thailand
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Target Disease Prevalence
    • 7.4.8.3. Competitive Scenario
    • 7.4.8.4. Regulatory Framework
    • 7.4.8.5. Reimbursement Scenario
    • 7.4.8.6. Thailand Sustained Release Excipients Market, 2018 - 2030 (USD Million)
• 7.5. Latin America
  • 7.5.1. SWOT Analysis
  • 7.5.2. Latin America Sustained Release Excipients Market, 2018 - 2030 (USD Million)
  • 7.5.3. Brazil
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Competitive Scenario
    • 7.5.3.4. Regulatory Framework
    • 7.5.3.5. Reimbursement Scenario
    • 7.5.3.6. Brazil Sustained Release Excipients Market, 2018 - 2030 (USD Million)
  • 7.5.4. Mexico
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Target Disease Prevalence
    • 7.5.4.3. Competitive Scenario
    • 7.5.4.4. Regulatory Framework
    • 7.5.4.5. Reimbursement Scenario
    • 7.5.4.6. Mexico Sustained Release Excipients Market, 2018 - 2030 (USD Million)
  • 7.5.5. Argentina
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Target Disease Prevalence
    • 7.5.5.3. Competitive Scenario
    • 7.5.5.4. Regulatory Framework
    • 7.5.5.5. Reimbursement Scenario
    • 7.5.5.6. Argentina Sustained Release Excipients Market, 2018 - 2030 (USD Million)
• 7.6. MEA
  • 7.6.1. SWOT Analysis
  • 7.6.2. MEA Sustained Release Excipients Market, 2018 - 2030 (USD Million)
  • 7.6.3. South Africa
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Competitive Scenario
    • 7.6.3.4. Regulatory Framework
    • 7.6.3.5. Reimbursement Scenario
    • 7.6.3.6. South Africa Sustained Release Excipients Market, 2018 - 2030 (USD Million)
  • 7.6.4. Saudi Arabia
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Competitive Scenario
    • 7.6.4.4. Regulatory Framework
    • 7.6.4.5. Reimbursement Scenario
    • 7.6.4.6. Saudi Arabia Sustained Release Excipients Market, 2018 - 2030 (USD Million)
  • 7.6.5. UAE
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Competitive Scenario
    • 7.6.5.4. Regulatory Framework
    • 7.6.5.5. Reimbursement Scenario
    • 7.6.5.6. UAE Sustained Release Excipients Market, 2018 - 2030 (USD Million)
  • 7.6.6. Kuwait
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Target Disease Prevalence
    • 7.6.6.3. Competitive Scenario
    • 7.6.6.4. Regulatory Framework
    • 7.6.6.5. Reimbursement Scenario
    • 7.6.6.6. Kuwait Sustained Release Excipients Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
  • 8.2.1. New Product Launch
  • 8.2.2. Partnerships
  • 8.2.3. Acquisition
  • 8.2.4. Collaboration
  • 8.2.5. Funding
• 8.3. Key Company Market Share Analysis, 2022
• 8.4. Company Profiles
  • 8.4.1. BASF SE
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. International Flavors & Fragrances, Inc.
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. Ashland Global
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Evonik Industries Inc
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. Croda International Plc
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. Gattefosse
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. Merck KGaA
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic Initiatives